Nitsche, Mirko

[["dc.bibliographiccitation.firstpage","819"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Rehabilitation Medicine"],["dc.bibliographiccitation.lastpage","823"],["dc.bibliographiccitation.volume","48"],["dc.contributor.author","Costa-Ribeiro, A"],["dc.contributor.author","Maux, A"],["dc.contributor.author","Bosford, T"],["dc.contributor.author","Tenório, Y"],["dc.contributor.author","Marques, D"],["dc.contributor.author","Carneiro, M"],["dc.contributor.author","Nitsche, M"],["dc.contributor.author","Filho, A"],["dc.contributor.author","Monte-Silva, K"],["dc.date.accessioned","2020-12-10T18:43:47Z"],["dc.date.available","2020-12-10T18:43:47Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.2340/16501977-2134"],["dc.identifier.issn","1650-1977"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78227"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Dopamine-independent effects of combining transcranial direct current stimulation with cued gait training on cortical excitability and functional mobility in Parkinson’s disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1254"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Arteriosclerosis, Thrombosis, and Vascular Biology"],["dc.bibliographiccitation.lastpage","1259"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Schäfer, Katrin"],["dc.contributor.author","Schroeter, Marco R."],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Weiss, Elisabeth"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.date.accessioned","2017-09-07T11:52:41Z"],["dc.date.available","2017-09-07T11:52:41Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective - To investigate the ability of bone marrow ( BM) - derived cells to modulate neointimal growth after injury by expressing plasminogen activator inhibitor-1 ( PAI-1). Methods and Results - We performed BM transplantation ( BMT) in lethally irradiated wild- type ( WT) and PAI-1-/- mice. Three weeks after carotid injury with ferric chloride, analysis of Y-chromosome DNA expression in the vessel wall of female hosts revealed that 20.8 +/- 6.0% of the cells in the neointima and 37.6 +/- 5.7% of those in the media were of BM origin. Lack of PAI-1 in either the host or the donor cells did not affect recruitment of BM-derived cells into sites of vascular injury. The neointima consisted predominantly of smooth muscle cells, and a proportion of these cells expressed PAI-1. Overall, lack of PAI-1 was associated with enhanced neointimal formation. However, importantly, BMTWT -> PAI-1-/- mice exhibited reduced neointimal area ( P = 0.05) and luminal stenosis ( P = 0.04) compared with BMTPAI-1-/--> PAI-1-/- mice. Although PAI-1-expressing cells were shown to be present in BMTWT -> PAI-1-/- lesions, these mice did not exhibit detectable levels of the inhibitor in the circulation, suggesting that local production of PAI-1 by cells in the neointima and media was sufficient to reduce luminal stenosis. Conclusions - PAI-1 from BM-derived cells appears capable of suppressing neointimal growth after vascular injury."],["dc.identifier.doi","10.1161/01.ATV.0000215982.14003.b7"],["dc.identifier.gro","3143681"],["dc.identifier.isi","000237644000012"],["dc.identifier.pmid","16514083"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1221"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1079-5642"],["dc.title","Plasminogen Activator Inhibitor-1 From Bone Marrow–Derived Cells Suppresses Neointimal Formation After Vascular Injury in Mice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","699"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Medizinische Klinik - Intensivmedizin und Notfallmedizin"],["dc.bibliographiccitation.lastpage","707"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Friesecke, S."],["dc.contributor.author","Träger, K."],["dc.contributor.author","Schittek, G. A."],["dc.contributor.author","Molnar, Z."],["dc.contributor.author","Bach, F."],["dc.contributor.author","Kogelmann, K."],["dc.contributor.author","Bogdanski, R."],["dc.contributor.author","Weyland, A."],["dc.contributor.author","Nierhaus, A."],["dc.contributor.author","Nestler, F."],["dc.contributor.author","Olboeter, D."],["dc.contributor.author","Tomescu, D."],["dc.contributor.author","Jacob, D."],["dc.contributor.author","Haake, H."],["dc.contributor.author","Grigoryev, E."],["dc.contributor.author","Nitsch, M."],["dc.contributor.author","Baumann, A."],["dc.contributor.author","Quintel, M."],["dc.contributor.author","Schott, M."],["dc.contributor.author","Kielstein, J. T."],["dc.contributor.author","Meier-Hellmann, A."],["dc.contributor.author","Born, F."],["dc.contributor.author","Schumacher, U."],["dc.contributor.author","Singer, M."],["dc.contributor.author","Kellum, J."],["dc.contributor.author","Brunkhorst, F. M."],["dc.date.accessioned","2020-12-10T14:07:57Z"],["dc.date.available","2020-12-10T14:07:57Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00063-017-0342-5"],["dc.identifier.eissn","2193-6226"],["dc.identifier.issn","2193-6218"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70342"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Internationales Register zur Nutzung des Adsorbers CytoSorb® bei Intensivpatienten"],["dc.title.alternative","International registry on the use of the CytoSorb® adsorber in ICU patients. Study protocol and preliminary results"],["dc.title.subtitle","Studienprotokoll und erste Ergebnisse"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1113"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","1120"],["dc.bibliographiccitation.volume","138"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Lederer, Katinka"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T09:08:54Z"],["dc.date.available","2018-11-07T09:08:54Z"],["dc.date.issued","2012"],["dc.description.abstract","Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models. We designed a phase I trial exploring concurrent fludarabine and radiotherapy in patients with advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerated dose (MTD) of fludarabine given with concurrent irradiation. Thirteen patients with stage IIIB NSCLC received thoracic irradiation of 60 Gy. Fludarabine was administered during the 5th and 6th week of radiotherapy. Doses started at 10 mg/m(2) per day and increased by steps of 3 mg/m(2) per day. At a daily dose of 16 mg/m(2), one out of six patients developed a grade 4 leukopenia, and one a grad 3 pneumonitis. Further grade III toxicity was not observed. The dose of 13 mg/m(2) was identified as the MTD. All patients developed a fludarabine dose-dependent lymphocytopenia. Fludarabine can be safely administered concurrently with radiation at a daily dose of 13 mg/m(2) during the final 2 weeks of radiotherapy. Further prospective clinical studies are required to establish the potential role of concurrent fludarabine and radiotherapy in the treatment of locally advanced inoperable NSCLC."],["dc.identifier.doi","10.1007/s00432-012-1185-3"],["dc.identifier.isi","000305196200004"],["dc.identifier.pmid","22402597"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8813"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26140"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0171-5216"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","195"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","202"],["dc.bibliographiccitation.volume","183"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Fest, Jan"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Gruendker, Carsten"],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Schmidberger, Heinz"],["dc.date.accessioned","2018-11-07T11:03:57Z"],["dc.date.available","2018-11-07T11:03:57Z"],["dc.date.issued","2007"],["dc.description.abstract","Background and Purpose: Simultaneous radiotherapy with chemotherapy is a standard treatment for inoperable non-small cell lung cancer (NSCLC), but the clinical outcome still remains poor. To further intensify treatment, substances need to be identified, which increase the effect of radiation on tumor cells without further enhancing toxicity to normal tissue. Hormones have a different toxicity profile than radiation or cytostatic drugs. As NSCLC often express estrogen receptors (ERs), the combination of genistein or estradiol and radiation in vitro was investigated. Material and Methods: A549 NSCLC cells with an inducible expression of a mutated TP53 and fibroblasts of a male donor (DF-18) were examined. ER expression was immunocytologically confirmed in all studied cell lines. Clonogenic survival was measured after incubation of the cells with genistein or estradiol (0.01 mu M and 10 mu M as maximum clinically applicable dose) and irradiation with different doses (0-4 Gy). The differentiation state of fibroblasts after combined therapy was analyzed. Results: A549 cells expressing mutated TP53 were more radioresistant than TP53 wild-type cells. Incubation of nonfunctional TP53 cells with genistein or estradiol increased radiosensitivity in both tested concentrations. By contrast, radiosensitivity of A549 with wild-type TP53 and DF-18 was not altered by hormonal incubation. In DF-18 radiation induced growth arrest that was not increased by additional hormonal incubation. Conclusion: NSCLC cells with nonfunctional TP53 might be sensitized against radiation by genistein or estradiol. As genistein is better tolerable than estradiol in patients, additional studies are warranted to assess potential gains of this combination therapy."],["dc.identifier.doi","10.1007/s00066-007-1561-0"],["dc.identifier.isi","000245452600006"],["dc.identifier.pmid","17406801"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51725"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","0179-7158"],["dc.title","Radiosensitization dependent on p53 function in bronchial carcinoma cells by the isoflavone genistein and estradiol in vitro"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1544"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Nature Neuroscience"],["dc.bibliographiccitation.lastpage","1553"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Mildner, Alexander"],["dc.contributor.author","Schmidt, Hauke"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Merkler, Doron"],["dc.contributor.author","Hanisch, Uwe-Karsten"],["dc.contributor.author","Mack, Matthias"],["dc.contributor.author","Heikenwalder, Mathias"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Priller, Josef"],["dc.contributor.author","Prinz, Marco R."],["dc.date.accessioned","2018-11-07T10:49:48Z"],["dc.date.available","2018-11-07T10:49:48Z"],["dc.date.issued","2007"],["dc.description.abstract","Microglia are crucially important myeloid cells in the CNS and constitute the first immunological barrier against pathogens and environmental insults. The factors controlling microglia recruitment from the blood remain elusive and the direct circulating microglia precursor has not yet been identified in vivo. Using a panel of bone marrow chimeric and adoptive transfer experiments, we found that circulating Ly-6C(hi)CCR2(+) monocytes were preferentially recruited to the lesioned brain and differentiated into microglia. Notably, microglia engraftment in CNS pathologies, which are not associated with overt blood-brain barrier disruption, required previous conditioning of brain (for example, by direct tissue irradiation). Our results identify Ly-6C(hi)CCR2(+) monocytes as direct precursors of microglia in the adult brain and establish the importance of local factors in the adult CNS for microglia engraftment."],["dc.identifier.doi","10.1038/nn2015"],["dc.identifier.isi","000251172900011"],["dc.identifier.pmid","18026096"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48513"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1097-6256"],["dc.title","Microglia in the adult brain arise from Ly-6C(hi)CCR2(+) monocytes only under defined host conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","227"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Cell and Tissue Research"],["dc.bibliographiccitation.lastpage","242"],["dc.bibliographiccitation.volume","334"],["dc.contributor.author","Kanwar, Namita"],["dc.contributor.author","Fayyazi, Afshin"],["dc.contributor.author","Backofen, Bianca"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","von Mollard, Gabriele Fischer"],["dc.date.accessioned","2018-11-07T11:09:20Z"],["dc.date.available","2018-11-07T11:09:20Z"],["dc.date.issued","2008"],["dc.description.abstract","SNARE (soluble-N-ethylmaleimide-sensitive factor attachment receptor) proteins mediate the recognition and fusion of transport vesicles in eukaryotic cells. The SNARE protein VAMP8 (also called endobrevin) is involved in the fusion of late endosomes and in some pathways of regulated exocytosis. In a subset of mice deficient for the SNARE protein VAMP8, a severe alteration of the thymus and in T lymphocyte development was observed and characterized. The size of the thymus and the number of thymocytes were dramatically reduced compared with those in heterozygous littermates. Further, the compartmentalization into cortex and medulla and the organization of the thymus epithelium were disturbed. The numbers of all thymocyte subpopulations were reduced, with the CD4 and CD8 double-positive thymocytes being most severely affected. The proportion of proliferating thymocytes was reduced, and the staining of apoptotic cells in situ and ex vivo indicated an increased number of apoptotic cells. Isolated thymocytes of Vamp8 mice were more susceptible to various apoptotic stimuli including glucocorticoids, FAS receptor, and CD3/CD28-mediated signaling in vitro, even before an increased number of apoptotic cells was detectable in situ. However, bone marrow of phenotypically affected Vamp8 mice was readily able to repopulate immunodeficient hosts suggesting that the SNARE protein VAMP8 has a specific function in the thymic stroma affecting the proliferation and apoptosis of T lymphocytes during maturation in the thymus."],["dc.identifier.doi","10.1007/s00441-008-0692-7"],["dc.identifier.isi","000260682800007"],["dc.identifier.pmid","18923845"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6753"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52986"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0302-766X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Thymic alterations in mice deficient for the SNARE protein VAMP8/endobrevin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","31"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","31"],["dc.bibliographiccitation.journal","Radiation Oncology"],["dc.bibliographiccitation.lastpage","10"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Schwarten, Dag"],["dc.contributor.author","Fister, Stefanie"],["dc.contributor.author","Grundker, Carsten"],["dc.contributor.author","Rave-Frank, Margret"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T10:59:33Z"],["dc.date.available","2018-11-07T10:59:33Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: Oncological results of radiotherapy for locally advanced prostate cancer (PC) are significantly improved by simultaneous application of LHRH analoga (e. g. goserelin). As 85% of PC express LHRH receptors, we investigated the interaction of goserelin incubation with radiotherapy under androgen-deprived conditions in vitro. Methods: LNCaP and PC-3 cells were stained for LHRH receptors. Downstream the LHRH receptor, changes in protein expression of c-fos, phosphorylated p38 and phosphorylated ERK1/2 were analyzed by means of Western blotting after incubation with goserelin and irradiation with 4 Gy. Both cell lines were incubated with different concentrations of goserelin in hormone-free medium. 12 h later cells were irradiated (0 - 4 Gy) and after 12 h goserelin was withdrawn. Endpoints were clonogenic survival and cell viability (12 h, 36 h and 60 h after irradiation). Results: Both tested cell lines expressed LHRH-receptors. Changes in protein expression demonstrated the functional activity of goserelin in the tested cell lines. Neither in LNCaP nor in PC-3 any significant effects of additional goserelin incubation on clonogenic survival or cell viability for all tested concentrations in comparison to radiation alone were seen. Conclusion: The clinically observed increase in tumor control after combination of goserelin with radiotherapy in PC cannot be attributed to an increase in radiosensitivity of PC cells by goserelin in vitro."],["dc.description.sponsorship","Deutsche Krebshilfe [106240]"],["dc.format.mimetype","application/pdf"],["dc.identifier.doi","10.1186/1748-717X-2-31"],["dc.identifier.fs","119077"],["dc.identifier.isi","000260343200001"],["dc.identifier.pmid","17718927"],["dc.identifier.ppn","559810636"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4370"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50728"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1748-717X"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","616"],["dc.title","No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro"],["dc.title.subtitle","Research"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1814"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","1823"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Uhmann, Anja"],["dc.contributor.author","Dittmann, Kai"],["dc.contributor.author","Nitzki, Frauke"],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","Koleva, Milena"],["dc.contributor.author","Frommhold, Anke"],["dc.contributor.author","Zibat, Arne"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Adham, Ibrahim M."],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Heller, Tanja"],["dc.contributor.author","Armstrong, Victor"],["dc.contributor.author","Schulz-Schaeffer, Walter J."],["dc.contributor.author","Wienands, Juergen"],["dc.contributor.author","Hahn, Heidi"],["dc.date.accessioned","2018-11-07T10:58:34Z"],["dc.date.available","2018-11-07T10:58:34Z"],["dc.date.issued","2007"],["dc.description.abstract","A first step in hematopoiesis is the specification of the lymphoid and myeloid lineages from multipotent progenitor cells in the bone marrow. Using a conditional ablation strategy in adult mice, we show that this differentiation step requires Patched (Ptch), the cell surface-bound receptor for Hedgehog (Hh). In the absence of Ptch, the development of T- and B-lymphoid lineages is blocked at the level of the common lymphoid progenitor in the bone marrow. Consequently, the generation of peripheral T and B cells is abrogated. Cells of the myeloid lineage develop normally in Ptch mutant mice. Finally, adoptive transfer experiments identified the stromal cell compartment as a critical Ptch-dependent inducer of lymphoid versus myeloid lineage commitment. Our data show that Ptch acts as a master switch for proper diversification of hematopoietic stem cells in the adult organism."],["dc.identifier.doi","10.1182/blood-2007-02-075648"],["dc.identifier.isi","000249671700022"],["dc.identifier.pmid","17536012"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50494"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","0006-4971"],["dc.title","The Hedgehog receptor Patched controls lymphoid lineage commitment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","447"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","452"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Prinz, Marco"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Weiss, Elisabeth"],["dc.date.accessioned","2021-06-01T10:49:17Z"],["dc.date.available","2021-06-01T10:49:17Z"],["dc.date.issued","2005"],["dc.identifier.doi","10.1007/s10147-005-0529-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86233"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1437-7772"],["dc.relation.issn","1341-9625"],["dc.title","Paraganglioma of the cerebellum: case report and review of the literature"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]